Table 1.
Clinical characteristics of patients.
| Characteristics | Control (n = 50) | CAD (n = 182) | p | SAP (n = 40) | NSTEACS (n = 90) | STEMI (n = 52) |
|---|---|---|---|---|---|---|
| Age (years) | 56.7 ± 11.7 | 59.18 ± 11.1 | 0.178 | 62.4 ± 10.0 | 60.6 ± 9.9 | 54.1 ± 12.3##&& |
| Male/female | 28/22 | 133/49 | 0.032 | 25/15 | 60/30 | 36/16 |
| BMI | 23.6 ± 3.1 | 24.2 ± 3.5 | 0.328 | 23.8 ± 3.1 | 23.9 ± 3.5 | 24.9 ± 3.8 |
| Risk factors | ||||||
| Hypertension, n (%) | 0 | 72 (40%) | — | 17 (43%) | 35 (39%) | 20 (39%) |
| Diabetes, n (%) | 7 (14%) | 24 (13%) | 0.882 | 2 (5%) | 13 (14%) | 9 (17%) |
| Dyslipidemia, n (%) | 0 | 29 (16%) | — | 7 (18%) | 16 (18%) | 6 (12%) |
| Smoking, n (%) | 12 (24%) | 119 (65%) | <0.001∗∗ | 18 (45%) | 61 (68%)∗∗# | 40 (77%)∗∗## |
| Family history, n (%) | 0 | 39 (21%) | — | 7 (18%) | 19 (21%) | 13 (25%) |
| Medications | ||||||
| Aspirin, n (%) | 0 | 51 (28%) | 15 (38%) | 24 (27%) | 12 (23%) | |
| Clopidogrel, n (%) | 0 | 8 (4%) | — | 3 (8%) | 2 (2%) | 3 (6%) |
| Beta-blockers, n (%) | 0 | 51 (28%) | — | 17 (43%) | 24 (27%) | 10 (19%)# |
| ACEI, n (%) | 0 | 53 (29%) | — | 10 (25%) | 28 (31%) | 15 (29%) |
| ARB, n (%) | 0 | 30 (16%) | — | 9 (23%) | 12 (13%) | 9 (17%) |
| CCB, n (%) | 0 | 45 (25%) | — | 13 (33%) | 20 (22%) | 12 (23%) |
| Statins, n (%) | 0 | 46 (25%) | — | 18 (45%) | 18 (20%)## | 10 (19%)## |
∗ p < 0.05 versus control, ∗∗ p < 0.01 versus control, # p < 0.05 versus SAP, ## p < 0.01 versus SAP, & p < 0.05 versus NSTEACS, && p < 0.01 versus NSTEACS.